Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows strong financial performance with a 20% revenue growth excluding a large client, a double-digit increase in EBITDA, and a significant rise in operating cash flow. Share repurchases further indicate confidence. Despite some margin compression and conservative guidance, the company is expanding its product offerings and has a positive outlook on membership and revenue growth. The Q&A section reveals some uncertainties, but overall sentiment remains positive. Given the company's market cap, a 2% to 8% stock price increase is likely over the next two weeks.
Key Financial Performance
Revenue $1.29 billion in 2025, a 10% increase year-over-year (20% increase excluding the impact of a large former client). The growth was driven by strong member engagement and prioritization of care by members.
Adjusted EBITDA $222 million in 2025, reflecting a double-digit increase over 2024. This was supported by operational efficiencies and economies of scale.
Operating Cash Flow $210 million in 2025, a 17% increase year-over-year. The increase was attributed to disciplined management and high conversion rates of adjusted EBITDA to cash.
Gross Margin Expanded by nearly 200 basis points in 2025 compared to 2024. This was due to efficiencies in care management and service delivery, as well as leverage with third-party partners.
CapEx $18.4 million in 2025, compared to $5.4 million in 2024. The increase was due to investments in expanding the product platform and laying the foundation for future growth.
Share Repurchase Repurchased more than 3.3 million shares for nearly $84 million in Q4 2025, with a total of approximately 6.5 million shares repurchased under the program.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Progyny Select: A new solution targeting smaller employers under fully insured plans, offering a fixed premium product for cost predictability. This expands Progyny's market to 50 million lives in the U.S. under fully insured plans. Operational infrastructure is already in place for efficient distribution.
Market Expansion: Progyny is broadening its target market to include smaller employers and fully insured plans, in addition to its traditional focus on large self-insured employers. This includes universities, school systems, labor populations, and government entities.
Revenue Growth: Achieved $1.29 billion in revenue in 2025, a 10% increase year-over-year, or 20% excluding a former client. Revenue exceeded expectations by $90 million.
Client Retention: Maintained nearly 100% client retention, including all largest employers. 30% of the client base expanded their benefits for 2026.
Operational Efficiencies: Achieved a 200 basis point expansion in gross margin for 2025, driven by efficiencies in care management and service delivery. Adjusted EBITDA margin also increased.
Strategic Shift: Progyny is entering the fully insured market with Progyny Select, targeting smaller employers. This marks a shift from its traditional focus on large self-insured employers.
Diversification: Further diversified client and industry base, with no single client accounting for more than a single-digit percentage of revenue and no industry comprising more than 15% of lives.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Client Retention and Revenue Concentration: While Progyny has achieved near 100% client retention, the company faces risks related to revenue concentration. No single client accounts for more than a single-digit percentage of revenue, but any loss of a major client could still have a material impact on financial performance.
Economic Pressures and Cost Management: Despite holding costs below industry trends, the company operates in a healthcare environment with record medical cost inflation. This could challenge its ability to maintain cost advantages and profitability.
Market Expansion Challenges: The company is entering the fully insured market with Progyny Select, targeting smaller employers. This is a new market segment, and there are risks associated with execution, cost predictability, and adoption rates.
Client Population Adjustments: A net reduction in covered lives for 2026 due to administrative updates from clients could impact revenue projections, even though utilization rates remain unaffected.
Stock-Based Compensation and Leadership Changes: The departure of the company's President led to accelerated stock-based compensation expenses, impacting financials. Leadership transitions could also pose strategic and operational risks.
Revenue Growth Variability: Revenue growth is projected to slow, with a range of 5.1% to 9% for 2026. This includes the impact of losing a large client in 2025, which could affect investor confidence.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Projected revenue for 2026 is between $1.355 billion to $1.405 billion, reflecting growth of 5.1% to 9%. Excluding the $48.5 million revenue from a former client in 2025, growth is projected to be between 9.3% to 13.3%.
Profitability: Expected adjusted EBITDA for 2026 is between $224 million to $239 million. Net income is projected to be between $95.4 million to $106.1 million, equating to $1.19 to $1.22 in earnings per diluted share and $1.83 to $1.95 of adjusted EPS.
Stock-Based Compensation: Stock-based compensation expense is expected to decrease by approximately 35% in 2026 compared to 2025, representing about 6% of revenue at the midpoint.
First Quarter 2026 Guidance: Revenue is projected to be between $319 million to $332 million, reflecting growth of negative 1.6% to positive 2.5%. Excluding the $31.3 million revenue from a former client in Q1 2025, growth is projected to be 9% to 13.4%. Adjusted EBITDA is expected to be between $51 million to $55 million, with net income of $20.8 million to $23.7 million.
Member Engagement and Utilization: Utilization rates for 2026 are assumed to range from 1.04% to the midpoint of historical ranges. ART cycles per unique utilizer are expected to be 0.48 to 0.49 in Q1, with full-year consumption consistent with the last two years.
New Market Opportunities: Progyny Select will target smaller employers under fully insured plans, addressing a market of 50 million lives in the U.S. This initiative is expected to contribute to financial results starting in 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: During the quarter, Progyny repurchased more than 3.3 million shares for nearly $84 million under its most recent share repurchase program, which began in November and provides up to $200 million overall. To date, including activity since January 1, Progyny has repurchased approximately 6.5 million shares in total, with more than $40 million remaining available under the authorization.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Were the mismatches in membership outlook for 2026 related to new clients or existing clients?
A:The mismatches were related to previously existing clients, not new clients. The changes were due to administrative updates from clients, which are not perfect and can be significant at the end of the year.
Q:What is the value of Progyny Rx amidst developments like the Federal bill requiring 100% rebate pass-through in 2028?
A:Progyny Rx has not faced pushback from employers. The model includes rebates at the point of sale since its introduction in 2018. While the structure of fees may evolve, the net economics are expected to remain unchanged due to the value delivered on medical and pharmacy sides.
Q:What is the strategy for pricing Progyny Select and managing associated risks?
A:Progyny Select pricing is based on underwriting experience from smaller clients. Guardrails are in place to manage risks, such as no opt-outs, mandatory coverage for all lives in smaller employers, and caps for high-cost claimants. The expectation is that as the pool grows, variability will decrease.
Q:Is the guidance for Q1 conservative, and what factors contribute to margin compression?
A:The guidance is based on current activity and includes some conservatism due to early-year data. Margin compression is due to ramping up the business, timing of platform investments, and product expansions.
Q:What are the swing factors in the guidance range for 2025?
A:Swing factors include treatment pace, treatment mix, utilization rates, and revenue from midyear or later client starts. The guidance does not include revenue from unsold clients.
Q:What is the financial impact of maternal health services and menopause solutions?
A:These services are growing but are not yet material. They are considered value-adds to the overall client services.
Q:What is the outlook for membership growth and revenue growth in 2026?
A:Membership is expected to grow in the mid- to high single digits, while revenue growth is projected in the low double digits. This is due to higher utilizing lives replacing lower utilizing ones and an element of rate increase.
Q:What is the predictability of Progyny Select as it scales?
A:Progyny Select is not yet predictable as it is still being marketed and will go live in 2027. Predictability is expected when the pool reaches a couple of hundred thousand lives, based on existing data and actuarial underwriting.
Q:What are the high-cost guardrails for Progyny Select?
A:Guardrails include a maximum dollar amount for high-cost claimants, after which employees become self-insured or cash pay. Claims do not revert to the employer.
Q:What is the expected CapEx and cash flow conversion for 2026?
A:CapEx is expected to step up but not double, reflecting the full-year impact of prior investments. Cash flow conversion is expected to align with the 75% metric from adjusted EBITDA to cash flow.
Q:What is the success of newer solutions like menopause programs?
A:These programs are marketed alongside fertility benefits and are supported by subject matter experts. Marketing is done in collaboration with client partners.
Q:Were there any industries with elevated administrative changes in membership?
A:No specific industries were identified; the changes were across various industries, primarily involving lower utilizing lives.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or clarity on the following: 1. The potential evolution of the Progyny Rx model and its fee structure. 2. Specific details on the high-cost guardrails for Progyny Select, such as the average attachment point. 3. The exact financial impact of newer solutions like menopause programs. 4. Industries with elevated administrative changes were not clearly identified.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI capability
Conference today
Federal Securities
Law result
Progyny Livingston
Progyny Select
Progyny access
Progyny high
Progyny upsells
Progyny value
Securities Law
Select contribution
Select solution
Sir floor
TAM vein
access experience
access premium
access type
acknowledgment need
addition TAM
addition cohort
building woman
client industry
decade
digit
distribution
employer plan
focus
health care
health member
member satisfaction
momentum
outcome cost
quality outcome
self market
solution family
PGNY Transcript
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call indicates strong financial performance with a positive revenue growth outlook, efficient cash management, and a completed share repurchase program. Despite some management vagueness on RFP activity and upsell details, the Q&A reveals positive sentiment towards early commitments and new client utilization. The market cap suggests a moderate reaction, so the stock price is likely to see a positive movement between 2% to 8% over the next two weeks.
Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call shows strong financial performance with a 20% revenue growth excluding a large client, a double-digit increase in EBITDA, and a significant rise in operating cash flow. Share repurchases further indicate confidence. Despite some margin compression and conservative guidance, the company is expanding its product offerings and has a positive outlook on membership and revenue growth. The Q&A section reveals some uncertainties, but overall sentiment remains positive. Given the company's market cap, a 2% to 8% stock price increase is likely over the next two weeks.
PGNY Slides
PGNY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
